Literature DB >> 19937404

Outcome of acute myeloid leukemia patients with hyperleukocytosis in Brazil.

L C O Oliveira1, L G M Romano, B P A Prado-Junior, D T Covas, E M Rego, G C De Santis.   

Abstract

Acute myeloid leukemia (AML) with a high white blood cell (WBC) count at presentation has been associated with an increased early mortality rate, usually secondary to leukostasis. However, the value of the WBC count at which there is a high risk of early death (ED) and the efficiency of supportive treatments remain unclear. In this report, a series of 187 consecutive adult patients with AML in our institution was reviewed. The outcome of 40 patients with WBC above 50×10(9) L(-1) (hyperleukocytosis) was compared to 147 patients with a leukocyte count lower than 50×10(9) L(-1). The group with hyperleukocytosis showed a significantly shorter OS (P<0.0001) and a higher rate of ED (P=0.0008). Even when the data from ED patients were removed from analysis, we still detected a shorter OS in patients with hyperleukocytosis (P=0.0049), which suggests that high WBC number influences long-term survival, and not only ED. We also observed higher lactic dehydrogenase (LDH) and serum creatinine levels in the group of patients with hyperleukocytosis (P=0.0003 and 0.0406, respectively). Besides considering all the patients with ED, we could observe higher levels of lactic dehydrogenase, a serum creatinine and nitrogen urea (P=0.0056, P=0.0008 and P<0.0001, respectively). Pulmonary involvement was more frequent in patients with ED (P=0.0277). In conclusion, hyperleukocytosis confers a poorer prognosis in patients with AML.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19937404     DOI: 10.1007/s12032-009-9367-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  23 in total

1.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

2.  Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival.

Authors:  F J Giles; Y Shen; H M Kantarjian; M J Korbling; S O'Brien; P Anderlini; M Donato; S Pierce; M J Keating; E J Freireich; E Estey
Journal:  Leuk Lymphoma       Date:  2001-06

3.  De novo acute myeloid leukemia in adults younger than 60 years of age: socioeconomic aspects and treatment results in a Brazilian university center.

Authors:  Evandro M Fagundes; Vanderson Rocha; Ana Beatriz F Glória; Nelma Cristina D Clementino; José S Quintão; João Paulo O Guimarães; Enio Roberto P Pedroso; Marcos B Viana
Journal:  Leuk Lymphoma       Date:  2006-08

4.  Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination.

Authors:  A Stucki; A S Rivier; M Gikic; N Monai; M Schapira; O Spertini
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

5.  Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis.

Authors:  A Thiébaut; X Thomas; A Belhabri; B Anglaret; E Archimbaud
Journal:  Ann Hematol       Date:  2000-09       Impact factor: 3.673

6.  Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia.

Authors:  M J Greenwood; M D Seftel; C Richardson; D Barbaric; M J Barnett; H Bruyere; D L Forrest; D E Horsman; C Smith; K Song; H J Sutherland; C L Toze; T J Nevill; S H Nantel; D E Hogge
Journal:  Leuk Lymphoma       Date:  2006-07

7.  Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.

Authors:  Ursula Creutzig; Martin Zimmermann; Dirk Reinhardt; Michael Dworzak; Jan Stary; Thomas Lehrnbecher
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

Review 8.  Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations.

Authors:  M A Lichtman; J M Rowe
Journal:  Blood       Date:  1982-08       Impact factor: 22.113

9.  Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival.

Authors:  J P Dutcher; C A Schiffer; P H Wiernik
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

10.  Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines.

Authors:  Rafael Henriques Jácomo; Raul Antonio Morais Melo; Fernanda Ribeiro Souto; Ederson Roberto de Mattos; Claudia Teresa de Oliveira; Evandro M Fagundes; Henrique Neves da Silva Bittencourt; Rosane Isabel Bittencourt; Teresa Cristina Bortolheiro; Eduardo J A Paton; Rodrigo Bendlin; Sebastião Ismael; Maria de Lourdes Chauffaille; Dirceu Silva; Katia Borgia B Pagnano; Raul Ribeiro; Eduardo M Rego
Journal:  Haematologica       Date:  2007-10       Impact factor: 9.941

View more
  9 in total

1.  Co-occurrence of hyperleukocytosis and elevated fibrin-fibrinogen degradation product levels is a risk factor for early intracranial hemorrhage in patients with de novo acute leukemia.

Authors:  Kunimoto Ichikawa; Yoko Edahiro; Akihiko Gotoh; Kazuhide Iiduka; Norio Komatsu; Michiaki Koike
Journal:  Int J Hematol       Date:  2016-07-25       Impact factor: 2.490

2.  Differentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment.

Authors:  E M Rego; G C De Santis
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-10-24       Impact factor: 2.576

3.  Demographic and prognostic factors of 455 patients with acute leukemia admitted to two referral hospitals in tehran-iran during ten years (2001-2011).

Authors:  Parvin Ayremlou; Seyed Mohsen Razavi; Masoud Solaymani-Dodaran; Masoud Vakili; Mohsen Asadi-Lari
Journal:  Iran J Cancer Prev       Date:  2012

4.  A hospital based retrospective study of factors influencing therapeutic leukapheresis in patients presenting with hyperleukocytic leukaemia.

Authors:  Yanxia Jin; Shishang Guo; Qin Cui; Sichao Chen; Xiaoping Liu; Yongchang Wei; Yunbao Pan; Liang Tang; Tingting Huang; Hui Shen; Guanghui Xu; Xuelan Zuo; Shangqin Liu; Hui Xiao; Fei Chen; Fayun Gong; Fuling Zhou
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

5.  Chest radiographic and CT findings in hyperleukocytic acute myeloid leukemia: A retrospective cohort study of 73 patients.

Authors:  Michael Stefanski; Carlos Jamis-Dow; Michael Bayerl; Ruchi J Desai; David F Claxton; Andry Van de Louw
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

6.  Prognostic Parameters of Acute Myeloid Leukaemia at Presentation.

Authors:  Azra Jahic; Ermina Iljazovic; Samira Hasic; Aida Custovic Arnautovic; Damir Sabitovic; Semir Mesanovic; Haris Sahovic; Vlastimir Simendic
Journal:  Med Arch       Date:  2017-02-05

7.  Analysis of Risk Factors of Coagulation Dysfunction and Hemorrhage in Newly Diagnosed Hyperleukocytic Acute Myeloma Leukemia.

Authors:  Anjie Xu; Pan Liu; Fuling Zhou
Journal:  Contrast Media Mol Imaging       Date:  2022-07-13       Impact factor: 3.009

8.  The role of therapeutic leukapheresis in hyperleukocytotic AML.

Authors:  Friederike Pastore; Alessandro Pastore; Georg Wittmann; Wolfgang Hiddemann; Karsten Spiekermann
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

9.  Hyperleukocytosis: A report of five cases and review of the literature.

Authors:  Junmei Gong; Bijia Wu; Tianjian Guo; Silang Zhou; Benfu He; Xinzhao Peng
Journal:  Oncol Lett       Date:  2014-07-08       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.